‪T Ciulla, TA Ciulla, Thomas Ciulla‬

Citée par

	Toutes	Depuis 2019
Citations	29164	9225
indice h	78	49
indice i10	201	137

2100

1050

525

1575

1999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202492 131 198 234 327 496 587 630 711 612 585 891 1190 1462 1630 1914 2040 1812 1683 1525 1446 1674 1970 1837 1630 543

Accès public

Tout afficher

47 articles

1 article

disponibles

non disponibles

Sur la base des exigences liées au financement

Coauteurs

Alon HarrisIcahn School of Medicine at Mount SinaiAdresse e-mail validée de mssm.edu
Ronald P DanisUniversity of Wisconsin School of Medicine and Public HealthAdresse e-mail validée de wisc.edu
Peter CampochiaroEccles Professor of Ophthalmology and Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MDAdresse e-mail validée de jhmi.edu
Jeffrey HeierAdresse e-mail validée de eyeboston.com
Gui-shuang YingCarolyn F. Jones Professor of OphthalmologyAdresse e-mail validée de pennmedicine.upenn.edu
Cynthia TothProfessor of Ophthalmology, Duke UniversityAdresse e-mail validée de duke.edu
David M Brown MD FACSDirector of Research, Retina Consultants of HoustonAdresse e-mail validée de houstonretina.com
L KagemannDepartment of Ophthalmology, New York University Langone School of MedicineAdresse e-mail validée de nyumc.org
Brent SieskyIcahn School of Medicine at Mount SinaiAdresse e-mail validée de mssm.edu
Peter KaiserProfessor of Ophthalmology, Cleveland Clinic Lerner College of MedicineAdresse e-mail validée de ccf.org
Steven YehEmory Eye Center, Emory University School of MedicineAdresse e-mail validée de emory.edu
Lloyd Paul Aiello, MD, PhDProfessor of Ophthalmology, Joslin Diabetes Center, Harvard Medical SchoolAdresse e-mail validée de joslin.harvard.edu
Elia DuhJohns Hopkins University School of MedicineAdresse e-mail validée de jhmi.edu
Christopher R. Henry MDRetina Consultants of HoustonAdresse e-mail validée de houstonretina.com
Stephen L. HauserUCSFAdresse e-mail validée de ucsf.edu
Mark L. Van NattaAssociate Scientist, Johns Hopkins Bloomberg School of Public HealthAdresse e-mail validée de jhsph.edu
Julia A. HallerProfessor, Wills Eye, Hopkins, JeffersonAdresse e-mail validée de willseye.org
Philip RosenfeldBascom Palmer Eye InstituteAdresse e-mail validée de miami.edu
Rahul N. KhuranaNorthern California Retina Vitreous AssociatesAdresse e-mail validée de ncrva.com
Mark R BarakatDirector of Clinical Research, Retina Macula Institute of ArizonaAdresse e-mail validée de azretinamacula.com

Suivre

T Ciulla, TA Ciulla, Thomas Ciulla

Chief Medical Officer, Viridian; Volunteer Clinical Professor, Indiana Univ Schl of Medicine

Adresse e-mail validée de midwesteye.com - Page d'accueil

AMD Diabetic Retinopathy Autoimmune Disease Gene Therapy Drug Delivery


Titre Trier par citations Trier par année Trier par titre	Citée par Citée par	Année
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results DF Martin, MG Maguire, SL Fine, G Ying, GJ Jaffe, JE Grunwald, C Toth, ... Ophthalmology 119 (7), 1388-1398, 2012	1956	2012
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results DF Martin, MG Maguire, SL Fine, G Ying, GJ Jaffe, JE Grunwald, C Toth, ... Ophthalmology 119 (7), 1388-1398, 2012	1928	2012
Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study DM Brown, M Michels, PK Kaiser, JS Heier, JP Sy, T Ianchulev Ophthalmology 116 (1), 57-65. e5, 2009	1716	2009
Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies TA Ciulla, AG Amador, B Zinman Diabetes care 26 (9), 2653-2664, 2003	1199	2003
Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study PA Campochiaro, JS Heier, L Feiner, S Gray, N Saroj, AC Rundle, ... Ophthalmology 117 (6), 1102-1112. e1, 2010	1177	2010
Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study DM Brown, PA Campochiaro, RP Singh, Z Li, S Gray, N Saroj, AC Rundle, ... Ophthalmology 117 (6), 1124-1133. e1, 2010	1067	2010
Vascular endothelial growth factor–induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform–selective inhibitor LP Aiello, SE Bursell, A Clermont, E Duh, H Ishii, C Takagi, F Mori, ... Diabetes 46 (9), 1473-1480, 1997	930	1997
Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study QD Nguyen, SM Shah, AA Khwaja, R Channa, E Hatef, DV Do, D Boyer, ... Ophthalmology 117 (11), 2146-2151, 2010	762	2010
Bacterial endophthalmitis prophylaxis for cataract surgery: an evidence-based update TA Ciulla, MB Starr, S Masket Ophthalmology 109 (1), 13-24, 2002	726	2002
Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes P Stalmans, MS Benz, A Gandorfer, A Kampik, A Girach, S Pakola, ... New England Journal of Medicine 367 (7), 606-615, 2012	700	2012
A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch … IU Scott, MS Ip, PC VanVeldhuisen, NL Oden, BA Blodi, M Fisher, ... Archives of ophthalmology 127 (9), 1115, 2009	682	2009
A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central … MS Ip, IU Scott, PC VanVeldhuisen, NL Oden, BA Blodi, M Fisher, ... Archives of ophthalmology 127 (9), 1101, 2009	657	2009
Intravitreal triamcinolone acetonide in exudative age-related macular degeneration RP Danis, TA Ciulla, LM Pratt, W Anliker Retina 20 (3), 244-250, 2000	657	2000
Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration BG Busbee, AC Ho, DM Brown, JS Heier, IJ Suñer, Z Li, RG Rubio, P Lai, ... Ophthalmology 120 (5), 1046-1056, 2013	576	2013
Ranibizumab and bevacizumab for neovascular age-related macular degeneration CATT Research Group New England Journal of Medicine 364 (20), 1897-1908, 2011	526	2011
Ranibizumab and bevacizumab for neovascular age-related macular degeneration CATT Research Group New England Journal of Medicine 364 (20), 1897-1908, 2011	526	2011
Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study JS Heier, AN Antoszyk, PR Pavan, SR Leff, PJ Rosenfeld, TA Ciulla, ... Ophthalmology 113 (4), 633-642. e4, 2006	526	2006
Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study QD Nguyen, SM Shah, JS Heier, DV Do, J Lim, D Boyer, P Abraham, ... Ophthalmology 116 (11), 2175-2181. e1, 2009	497	2009
Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema PA Campochiaro, DM Brown, A Pearson, T Ciulla, D Boyer, FG Holz, ... Ophthalmology 118 (4), 626-635. e2, 2011	475	2011
Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study JS Heier, DS Boyer, TA Ciulla, PJ Ferrone, JM Jumper, RC Gentile, ... Archives of Ophthalmology 124 (11), 1532-1542, 2006	395	2006

Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.

Articles 1–20

Nombre de citations par an

Citations en double

Citations fusionnées

Ajouter les coauteursCoauteurs

Suivre

Citée par

Coauteurs